Jeff P. Coon
Human Resources Officer chez DYNAVAX TECHNOLOGIES CORPORATION
Profil
Jeff P.
Coon is currently the Senior VP-Human Resources & Corporate Services at Dynavax Technologies Corp.
Prior to this, he held various human resources leadership positions at Johnson & Johnson, Cobham Ltd., PDL BioPharma, Inc., Assertio Therapeutics, Inc., Exelixis, Inc., Five Prime Therapeutics, Inc., and CD Holding, Inc. He received his undergraduate degree from The California State University and his graduate degree from Golden Gate University in 1994.
Postes actifs de Jeff P. Coon
| Sociétés | Poste | Début |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Human Resources Officer | 01/01/2019 |
Anciens postes connus de Jeff P. Coon
| Sociétés | Poste | Fin |
|---|---|---|
| FIVE PRIME THERAPEUTICS, INC. | Human Resources Officer | 01/01/2019 |
Assertio Therapeutics, Inc.
 Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Chief Administrative Officer | 01/01/2017 |
| COBHAM | Human Resources Officer | 01/08/2011 |
| EXELIXIS, INC. | Human Resources Officer | 01/01/2009 |
| PDL BIOPHARMA, INC. | Human Resources Officer | 01/01/2008 |
Formation de Jeff P. Coon
| The California State University | Undergraduate Degree |
| Golden Gate University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| EXELIXIS, INC. | Health Technology |
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| Entreprise privées | 5 |
|---|---|
Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Cobham Ltd.
 Cobham Ltd. Information Technology ServicesTechnology Services Cobham Ltd. designs and manufactures civil and military aerospace equipment and specialized systems and components. The firm offers refuelling equipment, aviation oxygen systems, weapon system containers, and rescue and navigation lights. The company was founded by Alan John Cobham on October 29, 1934 and is headquartered in Wimborne, the United Kingdom. | Technology Services |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
| CD Holding, Inc. | Consumer Services |
